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“The recognition of pathologies beyond the standard symptoms of infection has led 
to a greater appreciation of the public health consequences of trichomoniasis…”
Trichomoniasis is the most prevalent non-viral sexually transmitted disease worldwide and 
affects an estimated 170 million people [1]. The manifestations of infection with 
Trichomonas vaginalis, the causative agent of trichomoniasis, are primarily observed in 
women, and range from an asymptomatic presentation to copious, malodorous discharge and 
punctate epithelial lesions, known as strawberry cervix. Men can also present with urethritis, 
prostatitis and discharge, but the vast majority of T. vaginalis infections in men are 
asymptomatic. In addition to the observable symptoms in women, trichomoniasis has been 
associated with adverse outcomes in pregnancy, and increased susceptibility to and 
transmission of HIV-1 and cervical cancer [2,3]. The recognition of pathologies beyond the 
standard symptoms of infection has led to a greater appreciation of the public health 
consequences of trichomoniasis and the realization that its previous categorization as merely 
a nuisance infection, or simply a marker for other sexually transmitted infections, was 
erroneous [4,5].
Treatment for trichomoniasis has relied almost exclusively on drugs of the 5-nitroimidazole 
class. In the USA, trichomoniasis is treated with either metronidazole or tinidazole. 
Tinidazole has better molar efficacy against T. vaginalis isolates in vitro [6] and has fewer 
side effects than metronidazole. However, because of the similarities in chemical structure, 
infections that are highly resistant to metronidazole may also fail to cure after standard 
treatments with tinidazole.
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Both the action of the 5-nitroimidazoles and the specific mechanism of resistance in T. 
vaginalis isolates to these drugs remain poorly understood. In general, 5-nitroimidazoles 
enter the parasite by passive diffusion as a prodrug. Activation of the drug occurs within the 
parasite by redox enzymes involved in ATP production in the hydrogenosome and/or by 
flavin reductases, such as thioredoxin reductase [7,8]. Reduction of 5-nitroimidazoles 
produces cytotoxic radical anions that damage DNA and form adducts with critical parasite 
proteins. Laboratory-derived, drug-resistant isolates have lower intracellular concentrations 
of activated drug, which has been attributed to lower concentrations of the redox enzymes or 
coenzymes (e.g., FAD) responsible for drug activation or maintenance in a reduced form [8]. 
However, it is not clear that the mechanism(s) of resistance in laboratory-induced strains are 
accurate representations of 5-nitoimidazole insensitivity in clinically resistant infections 
[9,10]. Genetic analyses of T. vaginalis isolates demonstrate resistant isolates clustering 
within one of two primary subpopulations, suggesting that it will be possible to isolate 
molecular markers of drug resistance [11] [Conrad M et al., Population genetics of the 
sexually transmitted pathogen Trichomonas vaginalis and evidence for sexual recombination 
(2012), Manuscript submitted]. Identification of the mechanism of clinical drug resistance is 
a critical need for better understanding of the epidemiology of resistant infections as well as 
improving individual case management.
Resistance of T. vaginalis to 5-nitroimidazoles is quantitative and not qualitative; thus, 
infections that fail to cure with standard treatment doses can often be cleared with higher, 
more prolonged treatment with the same drugs [12]. This is clearly not an ideal strategy for 
dealing with drug-insensitive infections and may result in selection of more highly resistant 
strains. Women who repeatedly fail to cure trichomoniasis with 5-nitroimidazoles have few 
options. Alternative treatments for trichomoniasis utilize compounds that are not absorbed 
well from the intestinal tract (paromomycin sulfate, furazolidone) or are not ingestible 
(povidone iodine) and therefore must be administered intravaginally. While these 
compounds are very effective against trichomonads in vitro, intravaginal therapy tends to be 
less efficacious than systemic treatment in contacting and killing all parasites. Nevertheless, 
further research into utilization of intravaginal treatments, especially with povidone iodine 
pessaries, is needed.
Alternate therapies to treat trichomoniasis are also needed for persons allergic to 
metronidazole and tinidazole. Many individuals with hypersensitivity reactions to these 
drugs have relatively mild symptoms and can be successfully treated without severe side 
effects using short-course desensitization protocols [13]. Over the course of a single day, 
patients are administered metronidazole either orally or intravenously, starting with a very 
low dose of a few micrograms and gradually ramping up to a curative dose. However, some 
individuals can respond with an anaphylactic reaction or develop Stevens–Johnson 
syndrome following a single treatment [14,15]. For these women, the less effective 
intravaginal treatments are the only option. The situation is further complicated because it is 
difficult to obtain the intravaginal treatments as they require special formulation. Even 5-
nitroimidazole hypersensitive patients for whom the short-course desensitization protocols 
are indicated may find that the expense of formulating and administering the incremental 
doses is not covered by their health insurance.
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“Trichomoniasis is finally gaining the attention it warrants as a public health 
concern in developing as well as more industrialized countries.”
Thus, there is a clear need for identifying new therapies, preferably oral, that are effective 
against 5-nitroimidazole-resistant T. vaginalis infections and that can be used in patients 
allergic to this class of drugs. Unfortunately, like new drug development for most parasitic 
infections, there is little economic impetus to do so as the persons most heavily affected 
have very limited financial resources. Approximately 85% of trichomoniasis cases occur in 
developing countries, but even in the USA (and presumably other more industrialized 
countries), risk of infection is highest in minority populations in the lower socioeconomic 
tiers [1,16]. A number of novel compounds have demonstrated strong efficacy against T. 
vaginalis in vitro but have not progressed towards further testing because no pharmaceutical 
companies have selected them for development. In recent years, several companies have 
very generously donated drugs to treat helminth infections in resource-poor countries; 
however, it is a much more challenging prospect to develop and fully test a new compound 
that may never be profitable than to donate drugs that have known safety and efficacy, as 
well as marketability in nondonation settings.
In light of the difficulties in funding development of novel therapeutics specific for 
trichomoniasis, two approaches that may augment the armamentarium for treating resistant 
infections or persons with drug allergies are to identify existing approved drugs that can be 
used alone or in combination to cure infections or determine if new drugs being developed 
for other protozoan parasites also have activity against T. vaginalis. For the first approach, 
we recently screened 1024 compounds in vitro that are approved for human use by the US 
FDA or that are in Phase III trials in other studies [Goodhew EB et al., Manuscript in 
Preparation]. While we found no drugs that worked as well as the 5-nitroimidazoles, there 
were some that had clear partial efficacy. We are currently evaluating combinations of these 
drugs in vitro to determine if they can enhance the potency of 5-nitroimida-zoles against 
resistant isolates or provide viable alternatives for treating women with severe allergic 
reactions. The ‘piggyback’ approach appears plausible as aromatic diamidines designed for 
treatment of African trypanosomiasis show good efficacy in vitro against both 5-
nitroimidazole-susceptible and -resistant strains of T. vaginalis [17]. Unfortunately, clinical 
trials of one of these promising drugs were halted because of toxicity issues [18]. 
Nevertheless, as additional drugs from this class reach human testing, there is a reasonable 
expectation that they may also be effective against trichomonads. Other antiprotozoan drugs 
that kill trichomonads in vitro and might have efficacy against T. vaginalis infections 
include nitazoxanide (approved for use against giardiasis and cryptosporidiosis) and 
miltefosine (approved for treatment of human visceral leishmaniasis). However, 
nitazoxanide is poorly absorbed from the intestinal tract and therefore may only be an option 
for intravaginal treatment of trichomoniasis. No attempts at treatment of trichomoniasis 
using miltefosine have been reported and its teratogenic properties warrant extreme caution 
for use in women of child-bearing age.
Additional critical questions associated with treatment of trichomoniasis that compel further 
investigation pertain to persistence of infection following apparent cure, and whether it is 
important to detect and treat asymptomatic infections. Unlike most curable sexually 
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transmitted infections, the incidence and prevalence of trichomoniasis is higher in older 
sexually active women than in younger age groups [19]. The combination of the finding that 
another significant risk factor for T. vaginalis infection is history of previous trichomoniasis 
[19] with the observation that some women who have been previously infected and treated 
with apparent cure can again present with infection in the absence of additional sexual 
activity suggests that treatment of some infections only results in resolution of clinical signs 
without eradicating the infection [20]. Nucleic acid amplification tests have recently become 
commercially available and should be employed to systematically evaluate the frequency of 
symptomatic cure without parasite clearance and the effectiveness of other treatment 
regimens. The public health significance of asymptomatic infections and infections that 
persist following treatment needs further investigation. For example, are individuals with 
persistent or asymptomatic T. vaginalis infections a risk for transmitting trichomoniasis to 
their sex partners? Persons with asymptomatic infections are generally thought to harbor 
fewer parasites than individuals with clinical trichomoniasis and would therefore be less 
infectious. However, T. vaginalis-positive persons who do not know they are infected and 
thus do not seek treatment, especially men, may be unknowingly contributing to the spread 
of infection. Similarly, whether the presence of an asymptomatic infection increases a 
person’s risk of infection with HIV and other sexually transmitted infections, which are 
clearly associated with symptomatic trichomoniasis, requires investigation. Trichomoniasis 
is finally gaining the attention it warrants as a public health concern in developing as well as 
more industrialized countries. Continued research will lead to a better understanding of its 
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